IP Library Patent Application 17150361
Patent Application
App. No. 17/150,361

ORALLY DELIVERABLE FORMULATION TO PREVENT ALL CAUSE MORTALITY AND CARDIOVASCULAR EVENTS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/150,361
Abstract

The present disclosure describes materials and methods for providing the health benefits associated with chili peppers and cannabis to subjects in need thereof. For example, an oral formulation including at least one tissue from a fruit of the Capsicum genus, an extract therefrom, or a combination thereof, at least one cannabinoid, and a pharmaceutically acceptable excipient is provided. The oral formulation can be an oral spray, compressed tablet, or a candy-style lozenge.

Claims (28)

1 . An oral formulation comprising:

at least one tissue from a fruit of a species of Capsicum , an extract therefrom, or a combination thereof;

at least one cannabinoid; and

a pharmaceutically acceptable excipient.

2 . The oral formulation of claim 1 , wherein the at least one tissue is dried and ground.

3 . The oral formulation of claim 1 , comprising about 10 mg to 1000 mg tissue.

4 . The oral formulation of claim 3 , comprising about 100 mg to 500 mg tissue.

5 . The oral formulation of claim 1 , comprising a quantity of tissue sufficient to achieve a predetermined amount of polyphenol, flavonoid, or capsaicin in the formulation.

6 . The oral formulation of claim 1 , wherein the at least one tissue or extract therefrom lacks capsaicin or substantially lacks capsaicin.

7 . The oral formulation of claim 1 , wherein the at least one tissue or extract therefrom is selected from a cultivar with a Scoville heat unit (SHU) value of less than 50,000.

8 . The oral formulation of claim 1 , wherein the formulation is an oral spray.

9 . The oral formulation of claim 1 , wherein the formulation is a compressed tablet.

10 . The oral formulation of claim 1 , wherein the formulation is a candy-style lozenge.

11 . The oral formulation of claim 1 , further containing at least one sugar alcohol.

12 . The oral formulation of claim 1 , further comprising a hydrocolloid selected from the group consisting of gelatin, gum acacia, carob gum, carrageenan, ghatti gum, guar gum, karaya gum, pectin, tragacanth gum, locust bean gum, xanthan gum and combinations thereof.

13 . The oral formulation of claim 1 , wherein the pharmaceutically acceptable excipient is selected from the group consisting of emulsifiers, surfactants, colorants, flavorants, taste modifiers, buffering agents, pH adjusting agents, stabilizers, sweeteners and combinations thereof.

14 . The oral formulation of claim 1 , wherein the at least one cannabinoid comprises a water-soluble powder including at least one cannabinoid oil, isomalt, a hydrocolloid, and an emulsifier.

15 . The oral formulation of claim 14 , wherein the hydrocolloid is gum acacia and the emulsifier is quillaja extract.

16 . A method for improving health of a subject in need thereof comprising administering to the subject an oral formulation comprising:

at least one tissue from a fruit of a species of Capsicum , an extract therefrom, or a combination thereof;

at least one cannabinoid; and

a pharmaceutically acceptable excipient.

17 . The method of claim 16 , wherein the oral formulation is administered at least once a week for four weeks.

18 . The method of claim 17 , wherein the oral formulation is administered at least three times a week.

19 . A method for reducing the probability of a cardiac event in a patient in need thereof comprising administering to the patient an oral formulation comprising:

at least one tissue from a fruit of a species of Capsicum , an extract therefrom, or a combination thereof;

at least one cannabinoid; and

a pharmaceutically acceptable excipient.

Assignments (1)
SECURITY INTEREST Recorded Mar 4, 2022
From: RESURGENT BIOSCIENCES, INC.
To: CHICAGO ATLANTIC ADMIN, LLC
Reel/Frame 059172/0248 →